Welcome reception

DS working group session
Chairs: Eytan Stein & Courtney DiNardo

Session 1: Understanding the biology and pathogenesis of DS
Chairs: Eytan Stein & Courtney DiNardo

• Talk 1: Justin Watts
• Pathogenesis of DS: Stéphane de Botton
• Initial recognition of differentiation syndrome with ATRA in APL: Farhad Ravandi

Panel discussion

Session 2: Clinical presentations and treatment of DS
Chairs: Eytan Stein & Courtney DiNardo

• Talk 1: Ghayas Issa
• Talk 2: Eunice Wang
  
• Menin inhibitor syndrome: Treatment algorithm and future directions: Joshua Zeidner

Panel discussion

Session summary and close
Chairs: Eytan Stein & Courtney DiNardo

Welcome & introduction
Naval Daver 

Session 1: Translational and lab developments and applications in AML
Chairs: Ravindra Majeti & Stephen Nimer

• Telomeres and AML: Coleman Lindsley
• Understanding the biology and therapeutic potential of RAS in frontline AML and CMML: Sandra Misale
• Novel targets and targeting approaches for AML immunotherapy: John DiPersio

Panel discussion

Session 2: New science implications for AML
Chairs: John DiPersio & TBC

• Stem cells in human AML: Ravindra Majeti
• Role of Pi3K gamma inhibition in AML: Andrew Lane
• STAT3 inhibition in MDS and AML: Aditi Shastri
• Therapy-related MN: TBC

Panel discussion

Break

Keynote talk 1
Proposed updates to the classification of AML: key implications for clinical trials and clinical practice: Robert Hasserjian

Session 3: New frontiers in MRD for AML: Regulatory perspective and clinical practice
Chairs: Naval Daver & Eunice Wang

• Cell-free DNA determinants of AML MRD: Tian Yi Zhang
  
• Rapid epigenomic classification of acute leukemia: TBC
• MRD as a clinical endpoint in clinical trials: Updates from recent datasets: TBC
• MRD in AML: FDA’s regulatory perspective: Cara Rabik

Panel discussion

Day 1 conclusions
Andrew Wei

Welcome reception

Welcome to Day 2
Naval Daver 

Session 4: Updates on established therapies in AML
Chairs: Andrew Wei & Uma Borate

• Optimal approach to treatment of secondary/therapy-related AML: Harry Erba
• Optimal dose of VEN in AML therapy (OPTI-AML): Uma Borate
• Incorporating VEN to IC based induction – current status: Courtney DiNardo
• Optimal dose, duration and de-escalation of venetoclax: Stéphane de Botton

Panel discussion

Keynote talk 2
Targeting fundamental stem cell properties to treat AML: Stephen Nimer

Break

Session 5: Immunotherapies in AML
Chairs: Pinkal Desai & Roland Walter

• AVC-201: A CAR T using a switchable module in AML: Marion Subklewe
• SENTI-202: A logically gated off-the-shelf cell therapy for AML: Stephen Strickland
• Novel targets for T-cell engagers in relapsed/refractory AML: David Sallman
• CLN-049: TBC
• Pivekimab sunirine: Naval Daver

Panel discussion

Keynote talk 3
Talk title TBC: Scott Armstrong

Lunch

Session 6: Targeting FLT3-mutant AML
Chairs: Naval Daver & Amir Fathi

• Frontline approaches for fit patients with FLT3-mutant AML: Naval Daver
• PASHA study: TBC
• Current approaches and challenges for relapsed FLT3-mutant AML: Alexander Perl
• Managing FLT3-ITD+ AML in remission: Eunice Wang
• Resistance mechanisms: Catherine Smith

Panel discussion

Session 7: Value and utility of MRD in the management of adults with newly-diagnosed AML
Chairs: Farhad Ravandi & Gail Roboz

• Debate: NGS-based MRD (when available) is the key surrogate for outcomes for the management of fit adults with newly-diagnosed AML
  • For: Curtis Lachowiez
  • Against: Richard Stone

Panel discussion

 

Break

Session 8: Transplantation in AML
Chairs: Charles Craddock & Pramila Krishnamurthy

• Strategies to reduce relapse risk post transplant: Charles Craddock
• Precision-engineered T-cell immunotherapy for alloHSCT: TBC
• Debate: Is pre-transplant intervention warranted in patients with MRD+ AML CR1?
  • Yes: Tapan Kadia & Harry Erba
  • No: Uma Borate & Victoria Potter

Panel discussion

Session 9: Clonal hematopoiesis, BPDCN & CMML
Chairs: Naveen Pemmaraju & Uma Borate

• Potential for early intervention in CHIP and CCUS: Updates and ongoing trials: Uma Borate
• Blastic plasmacytoid dendritic cell neoplasm (BPDCN): New approaches: Naveen Pemmaraju
• Molecular biology and clinical outcomes of blast transformed CMML: Mrinal Patnaik
• Synthetic registries for clonal hematopoiesis: TBC

Panel discussion

Day 2 conclusions
Charles Craddock

 

Faculty dinner

Welcome to Day 3
Naval Daver

 

Session 10: Menin inhibitors in AML
Chairs: Naval Daver & Harry Erba

• Talk title TBC Justin Watts
• Talk title TBC: Ghayas Issa
• Breaking resistance: combinations and next-generation approaches in menin-driven AML: Emma Searle
  
• Frontline menin combinations with standard of care: Amer Zeidan
• Paradigm shift with menin inhibitor triplets: Moving beyond unfit/older AML: Joshua Zeidner

Panel discussion

Session 11: TP53-mutated AML
Chairs: David Sallman & Eunice Wang

• Biological insights and better understanding TP53m AML: TBC
  
• New approaches to target TP53m AML: Andrew Wei
• TP53-mutated AML and transplant: Pramila Krishnamurthy
• Current challenges and future strategies for TP53-mutated AML and MDS: Maximilian Stahl
• Talk title TBC: Gabriel Mannis

Panel discussion

Break

Session 12: Novel targets and advances in our understanding of AML
Chairs: Tapan Kadia & TBC

• Beyond genomics: Soluble proteomics in AML: Hussein Abbas
• Molecular complexity in AML: Ann-Kathrin Eisfeld
• Novel targets in AML and their implications for the practicing hematopathologist: Sanam Loghavi
• Reactivating apoptosis in AML: Direct BAX activation as a novel therapeutic strategy: Marina Konopleva
• REM-422: Courtney DiNardo

Panel discussion       

Session 13: Novel combinations and treatments in AML (part 1)
Chairs: Marina Konopleva & Tara Lin

• Intensive or non-intensive induction (PARADIGM): Amir Fathi
• How and when to use oral decitabine in AML: Gail Roboz
• Combinations with AZA/VEN: Thomas Cluzeau
• Combination strategies: Hima Atluri

Session 14: Novel combinations and treatments in AML (part 2)
Chairs: Andrew Wei & Hima Atluri

• Diamond-01 trial (MEN1703 [SEL24]): Roland Walter
• Talk title TBC: Pinkal Desai
• RPT1G: TBC

Panel discussion

Meeting summary and close
Naval Daver